Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nerve growth factor - Genentech

Drug Profile

Nerve growth factor - Genentech

Alternative Names: Neuleze

Latest Information Update: 06 Apr 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen Boulder; Chiron Corporation; Genentech
  • Class Foot disorder therapies; Nerve growth factors; Neuroprotectants
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Diabetic neuropathies; Herpes simplex virus infections; Neuropathic pain; Peripheral nervous system diseases

Most Recent Events

  • 30 Jan 2004 No development reported - Clinical-Phase-Unknown for Alzheimer's disease in Japan (unspecified route)
  • 30 Jan 2004 No development reported - Clinical-Phase-Unknown for Alzheimer's disease in Sweden (unspecified route)
  • 30 Jan 2004 No development reported - Preclinical for Herpes simplex virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top